The Italian reimbursement system is unique in terms of its structure, especially also for innovative drugs. However, what does the new innovation pathway means to the industry and health care availability? How easy is it really to negotiate a premium price? Listen to the discussions and explanations of Dr Stefan Walzer and… Continue Reading
Consequential prescription drug pricing decisions in the United States increasingly involve high-stakes interactions between the manufacturer and the Institute for Clinical and Economic Review (ICER). Continue Reading
Dr. Patti Peeples, CEO and Founder of HealthEconomics.Com, recently sat down with Dr. Anupam Jena, Scientific Advisor, Precision Xtract, to discuss his latest research that expands the definition and measurement of value of novel therapies by using new health economics evidence. Continue Reading
Written By: Americans spend more on prescription drugs than anyone else in the world. In a move to address this, CVS Caremark announced in August that it would allow self-funded insurers to exclude from their plan any drug launched at… Continue Reading
Written by Swarali Tadwalkar, MPH, Guest Blogger and Research Intern at HealthEconomics.Com Drug prices are the fastest-growing part of healthcare costs, and everyone – from patients, to physicians, policy-makers, and pharmaceutical companies – are grappling with price-setting and drug value assessment.… Continue Reading
